14 September 2022Place:
DOC Generici, the second largest operator in the Italian market of equivalent drugs and successfully present in the ophthalmology market for 5 years, announced that it has signed a definitive agreement for the acquisition of 100% of Nuova Oftalmica S.r.l., a newly established company resulting from the transfer of the activities of Medivis relating to the production, distribution and marketing on the Italian territory of all medical devices, food for special medical purposes, food supplements, cosmetics and drugs.
As part of the operation, Medivis and DOC Generici have also finalized a collaboration agreement for the development of innovative products in the ophthalmic field, with Medivis which will concentrate its activities exclusively in the R&D field
Founded in 2000 in Catania, Medivis has always had its primary development engine in research. Thanks to the realization of 18 international patents, ranging from drug delivery, to the creation of nanotechnological platforms for the delivery of numerous molecules and the ophthalmic use of low-concentration Iodopovidone, Medivis is now recognized as one of the most innovative companies in the ophthalmology field. For years, the Company has in fact sensed the enormous potential of antiseptics for topical use and the modulation of the microbiome in ophthalmological medical therapy. In 2018 CAPEX Pharma acquired a qualified minority stake in Medivis, with the aim of supporting and accelerating the group's growth plan.
“Over the years Medivis has brought numerous innovations to the market; now we have decided to go back to our origins by concentrating all our energies on Research & Development" declared Nello Mangiafico, President of Medivis. "We are happy to have signed this agreement that we can define a win-win, between Medivis, which will be able to accelerate the development of its innovation platforms in ophthalmology, and DOC, which will see its competitive proposal on the market strengthened”.
Founded in 1996, DOC Generici is a leading company in the generic drugs sector and in the ophthalmology field with headquarters in Milan, with revenues in excess of 250 million euro and over 100 million in EBITDA. Thanks to the experience and specialization gained, the Company is able to market a broad portfolio of quality products at affordable prices. DOC Generici's portfolio includes over 250 molecules and approximately 600 SKUs covering all major therapeutic areas. DOC provides a highly diversified range of reimbursable and non-refundable to distributors and pharmacies in all Italian regions.
“We are proud of what we have built in recent years in the ophthalmology field thanks to the close collaboration with the medical profession, offering patients a wide range of quality products ", declared Riccardo Zagaria, CEO of DOC "This further strengthening of our list ophthalmic with the entry of market leading brands such as IODIM and CORTIVIS strengthens our position among the top companies on the market. Furthermore, the collaboration with Medivis will allow us to launch innovative products resulting from his research in Italy over the next few years”
The sale process, assisting Medivis’ shareholders, was run by CP Advisors, led by Salvo Mazzotta and Marco Garro.
Commenting on the transaction, Salvo Mazzotta, Managing Partner of CP Advisors stated: "We are pleased to have assisted Medivis’ shareholders in the process of enhancing their shareholding value and in creating with DOC the leading group in the Italian ophthalmology market, led by a talented management team with an innovative portfolio’s products. This transaction also represents the first exit of our investment company, Capex Pharma, which has successfully reached the objectives designed together with the entrepreneurs and the management team of Medivis four years ago. It has been a privilege for us to be part of the fantastic journey and we wish continue success to DOC and the new ophthalmic group.”